[22] Ren X, Lin LP, Ding J。 Vascular targeting agent-combretastatin A4 [J]。 Chin J New Drugs (中国新药杂志), 2007, 16: 1336−1341。
[23] Cai YC, Zou Y, Xian LJ。 Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents [J]。 Acta Pharm Sin (药学学报), 2010, 45: 283。288。
[24] Greene, T。 F。; Wang, S。; Greene, L。 M。; Nathwani, S。 M。; Pollock, J。 K。; Malebari, A。 M。; McCabe, T。; Twamley, B。; O’Boyle, N。 M。; Zisterer, D。 M。; Meegan, M。 J。Synthesis and biochemical evaluation of 3-phenoxy-1,4-diarylazetidin-2-ones as tubulin-targeting antitumor agentsJ。 Med。 Chem。 2016, 59, 90–113
[25] Perez-Perez, M。 J。; Priego, E。 M。; Bueno, O。; Martins, M。 S。; Canela, M。 D。; Liekens, S。Blocking blood flow to solid tumors by destabilizing tubulin: an approach to targeting tumor growth。 J。 Med。 Chem。 2016, 59, 8685–8711
[26] Sebastien F, Lianhu W, Emmanuel M, et al。 Design, Synthesis, BiologicalEvaluation, and Structure-Activity Relationships of Substituted Phenyl 4-(2-Oxoimidazolidin-l-yl)-benzenesulfonates as New Tubulin Inhibitors Mimicking CombretastatinA-4。[J]。 Journal of Medicinal Chemistry,2011,54,4559-4580
[27] Kruczynski A, Barret JM, Etiévant C, et al。 Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated vinca alkaloid [J]。 Biochem Pharmacol, 1998, 55: 635。648。
[28] Ding YF, Bao YM, An LJ。 Progress research of antitumor agents vinblastine analogues [J]。 Chin J Pharm (中国医药工业杂志), 2005, 36: 424。428。
[29] You QD。 Medicinal Chemistry (药物化学) [M]。 Beijing:Chemical Industry Press, 2007: 544。545。